Safety and efficacy of extended dosing intervals of denosumab in patients with solid cancers and bone metastases: a retrospective study

AIM: More than half of patients with breast, lung, or prostate cancer who have bone metastases have evidence of skeletal-related events (SREs). Denosumab is a fully human monoclonal antibody that binds to and neutralizes receptor activator of nuclear factor kappa-B ligand (RANKL) on osteoblasts and...

Descripción completa

Detalles Bibliográficos
Autores principales: Abousaud, Aseala I., Barbee, Meagan S., Davis, Christine C., Caulfield, Sarah E., Wang, Zeyuan, Boykin, Alexa, Carthon, Bradley C., Gogineni, Keerthi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768832/
https://www.ncbi.nlm.nih.gov/pubmed/33488782
http://dx.doi.org/10.1177/1758835920982859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768832/
https://www.ncbi.nlm.nih.gov/pubmed/33488782
http://dx.doi.org/10.1177/1758835920982859

Ejemplares similares